Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.
about
A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancerStereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.Hypofractionated radiotherapy for localized prostate cancer.The Role of Hypofractionated Radiotherapy in Prostate Cancer.ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 PatientsReducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database.First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.CyberKnife-based prostate cancer patient radioablation - early results of irradiation in 200 patientsPredicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure.Stereotactic radiotherapy for prostate cancer: A review and future directions.Safety and feasibility of prostate stereotactic ablative radiotherapy using multimodality imaging and flattening filter free.Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.
P2860
Q26738278-F376187F-B072-4B2C-8648-5D7515F9A21AQ36426682-5C3EE64B-5E6D-4767-BADD-5DFDC743F58AQ37175207-9B389491-E111-4778-8566-E1A28FC976E4Q37547386-AF4048BE-DF51-4405-8277-B6A0FDCC3286Q39200876-ED46E178-A948-43D4-AA1C-D6A44FB8F601Q39456200-D57780DD-5EA4-4322-8AF9-536662ABB8DBQ39736576-C77CD4E9-9D6A-402D-9562-C727B4B58608Q40982235-11347C5C-9742-4165-9CBB-9C04D4CD7187Q41276603-0BC36AAD-499C-443E-885E-36354839DF4EQ41608117-4240D889-DDD5-44FB-95C4-B63A6F07842DQ41633448-C2C5E12D-8E23-4CC2-BD2B-08B4417781D3Q41866253-5A7362AE-653E-42D1-9439-FD8413C446DAQ41960300-69C27DF7-C4BB-48D0-B52A-DB3A2730D212Q42702939-4934EC07-C69E-4B65-BF13-47A7D5A5970BQ48233697-F2719D6E-B54A-4DF0-AF62-273C22556C3CQ54358254-80AA786D-8B2A-43E2-9A9A-CBC221B0DD40
P2860
Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@ast
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@en
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@nl
type
label
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@ast
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@en
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@nl
prefLabel
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@ast
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@en
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@nl
P2860
P356
P1476
Quality of Life and Toxicity a ...... ostate Cancer, a 7-Year Study.
@en
P2093
Alan Jay Katz
Josephine Kang
P2860
P356
10.3389/FONC.2014.00301
P577
2014-10-28T00:00:00Z